"Normalization" of tumor blood vessels has shown promise to improve the efficacy of chemotherapeutics. In theory, anti-angiogenic drugs targeting endothelial VEGF signaling can improve vessel network structure and function, enhancing the transport of subsequent cytotoxic drugs to cancer cells. In practice, the effects are unpredictable, with varying levels of success. The predominant effects of anti-VEGF therapies are decreased vessel leakiness (hydraulic conductivity), decreased vessel diameters and pruning of the immature vessel network. It is thought that each of these can influence perfusion of the vessel network, inducing flow in regions that were previously sluggish or stagnant. Unfortunately, when anti-VEGF therapies affect vessel structure and function, the changes are dynamic and overlapping in time, and it has been difficult to identify a consistent and predictable normalization "window" during which perfusion and subsequent drug delivery is optimal. This is largely due to the non-linearity in the system, and the inability to distinguish the effects of decreased vessel leakiness from those due to network structural changes in clinical trials or animal studies. We have developed a mathematical model to calculate blood flow in complex tumor networks imaged by two- photon microscopy. The model incorporates the necessary and sufficient components for addressing the problem of normalization of tumor vasculature: i) lattice-Boltzmann calculations of the full flow field within the vasculature and within the tissue, ii) diffusion and convection of soluble species such as oxygen or drugs within vessels and the tissue domain, iii) distinct and spatially-resolved vessel hydraulic conductivities and permeabilities for each species, iv) erythrocyte particles advecting in the flow and delivering oxygen with real oxygen release kinetics, v) shear stress-mediated vascular remodeling. We propose to use this model, guided by multi-parameter intravital imaging of tumor vessel structure and function, to determine the structural and functional determinants of tumor vessel normalization.

Public Health Relevance

Tumor blood vessels are chronically immature and unstable, but anti-angiogenic drugs can induce their morphogenesis in a process resembling adaptive remodeling in wound healing. Unfortunately little is known about how the resulting structural and functional changes affects the delivery of oxygen or drugs to the tumor. We will apply a mathematical model to determine how changes in vessel leakiness and network structure individually influence oxygen and drug delivery throughout tumor.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA149285-03
Application #
8250392
Study Section
Bioengineering, Technology and Surgical Sciences Study Section (BTSS)
Program Officer
Li, Jerry
Project Start
2010-06-01
Project End
2014-04-30
Budget Start
2012-05-01
Budget End
2013-04-30
Support Year
3
Fiscal Year
2012
Total Cost
$320,632
Indirect Cost
$139,484
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Munn, Lance L; Padera, Timothy P (2014) Imaging the lymphatic system. Microvasc Res 96:55-63
Duda, Dan G; Munn, Lance L; Jain, Rakesh K (2013) Can we identify predictive biomarkers for antiangiogenic therapy of cancer using mathematical modeling? J Natl Cancer Inst 105:762-5
Kesler, Cristina T; Liao, Shan; Munn, Lance L et al. (2013) Lymphatic vessels in health and disease. Wiley Interdiscip Rev Syst Biol Med 5:111-24
Baish, James W; Stylianopoulos, Triantafyllos; Lanning, Ryan M et al. (2011) Scaling rules for diffusive drug delivery in tumor and normal tissues. Proc Natl Acad Sci U S A 108:1799-803
Kamoun, Walid S; Chae, Sung-Suk; Lacorre, Delphine A et al. (2010) Simultaneous measurement of RBC velocity, flux, hematocrit and shear rate in vascular networks. Nat Methods 7:655-60